Primary Hyperoxaluria

原发性高草酸尿症

• 批准号: 7934947
• 负责人: Dawn Schmautz Milliner
• 金额: $ 50.5万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-08 至 2014-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7934947
• 关键词: Address; Area; Betaine; Calculi; Childhood; Clinical; Clinical Data; Clinical Research; Clinical Trials; Collaborations; Cystinuria; Databases; Disease; Educational Materials; End stage renal failure; European; Foundations; Future; Genes; Genetic; Goals; Health Personnel; Hydroxyproline; Hyperoxaluria; Information Resources; Inherited; Injury; Instruction; International; Kidney; Kidney Failure; Medical; Metabolic; Molecular; Nephrocalcinosis; Nephrolithiasis; Online Systems; Outcome; Oxalates; Oxalobacter; Patient Care; Patients; Physicians; Pilot Projects; Primary Hyperoxaluria; Rare Diseases; Registries; Renal function; Research; Research Personnel; Scientist; Screening procedure; Site; Structure; Testing; Tissue Banking; Tissue Banks; cohort; early onset; effective therapy; experience; follow-up; improved; innovation; investigator training; oxalosis; tissue resource; treatment strategy

PROJECT SUMMARY (See instructions): Primary hyperoxaluria (PH) is the most severe of the stone diseases, causing recurring stones from childhood on and end stage renal failure. Progress toward effective treatments has been slow. Our experience with the International Primary Hyperoxaluria Registry (IPHR) has resulted in better understanding of disease expression, early recognition of factors associated with loss of renal function, has suggested treatment strategies likely to be successful, and has facilitated sufficient numbers of patients to test new treatments in clinical trials of betaine and Oxalobacter, to date. The goals of the current project are to: (1) Expand our current PH registry to determine the factors associated with nephrocalcinosis, stone formation, and renal injury (2) Generate testable hypotheses regarding mechanisms of renal injury in these diseases through registry findings, tissue resources, and pilot projects. (3) Explore new avenues of treatment. (4) Develop cohorts of well-characterized patients for future clinical studies, (5) Explore new areas of partnership with the Oxalosis and Hyperoxaluria Foundation (OHF) (6) Provide ready access to high quality resources and information for physicians and scientists and (7) Attract and train investigators to rare diseases research. We will accomplish these goals through a consortium of clinician and basic scientists expert in PH, a network of study sites, and close collaboration with the OHF to more effectively reach and educate health care providers and patients. The 4 Specific Aims are to: S.A. 1a. Expand the PH registry containing clinical data for longitudinal follow-up of patients, identifying wellcharacterized cohorts of patients available for future treatment studies. 1 b. Expand the PH tissue bank S.A. 2a. Identify genetic modifiers of disease expression, specifically early onset of ESRD 2b. Perform molecular screening of TGF p as a candidate modifier gene. S.A. 3. Evaluate hydroxyproline as a potential metabolic precursor of oxalate in PH types 1 and 2. S.A. 4a. Create web-based educational materials at the highest scientific and medical level, to allow creation of patient material by the Oxalosis and Hyperoxaluria Foundation for international dissemination. 4b. Provide high quality information and resources regarding PH for physicians, clinical and basic scientists. We will also apply our experience with the IPHR to create a similar structure and activities for other hereditary causes of nephrolithiasis and renal failure: cystinuria, APRT deficiency, and Dent disease. Synergies will allow rapid transfer of experience and advancement of patient care.

项目概述（见说明）：